Each year, more than 250,000 patients are treated with nearly every ophthalmic condition and more than 18,000 surgeries are performed. In addition to its international reputation as one of the premier providers of eye care in the world, Bascom Palmer is the largest ophthalmic care, research and educational facility in the southeastern United States. News & World Report, an honor it has received for the 16 th time and by Ophthalmology Times. Photodynamic therapy had already been in use in other areas of ophthalmology, but the standard combination of riboflavin and UV light used to strengthen the cornea was not effective at killing tough strains of bacteria and fungi.īascom Palmer Eye Institute, a University of Miami Hospital and Clinic, is ranked the nation's best in ophthalmology by U.S. Amescua turned to a team of biomedical engineers at Bascom Palmer's Ophthalmic Biophysics Center.
However, outcomes from the transplant surgeries were not always successful because the eye was inflamed due to infection, causing the immune system to reject the transplant.įrustrated by this conundrum, Dr. As the eye infections worsened, it increased the chances of a tear in the cornea, which requires transplant surgery. Guillermo Amescua was a medical fellow at Bascom Palmer Eye Institute almost a decade ago, he noticed that fungal eye infections were problematic for a large number of his patients. There are higher rates of fungal infection in places like South Florida with tropical climates. Fungal infections can be caused by humid climates, dirty contact lenses, and trauma to the eye. Photodynamic therapy is the use of chemicals and light to cure infection and strengthen the main structure of the eye, called the cornea. For more medical news and research, click here for the University of Miami's health news blog. To find a doctor or make an appointment visit the Bascom Palmer website or call (305) 243-2020. Guillermo Amescua is an ophthalmologist at Bascom Palmer Eye Institute, part of UHealth – University of Miami Health System.
0 kommentar(er)
